US 10,376,519 B2
Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
Jay Copeland Strum, Hillsborough, NC (US); John Emerson Bisi, Apex, NC (US); Patrick Joseph Roberts, Durham, NC (US); Ricky D. Gaston, Kalamazoo, MI (US); and Robert C. Gadwood, Portage, MI (US)
Assigned to G1 Therapeutics, Inc., Research Triangle Park, NC (US)
Filed by G1 Therapeutics, Inc., Research Triangle Park, NC (US)
Filed on Jul. 31, 2017, as Appl. No. 15/665,071.
Application 15/665,071 is a continuation of application No. 14/690,180, filed on Apr. 17, 2015, granted, now 9,717,735, issued on Aug. 1, 2017.
Claims priority of provisional application 61/980,895, filed on Apr. 17, 2014.
Claims priority of provisional application 61/980,939, filed on Apr. 17, 2014.
Claims priority of provisional application 61/980,918, filed on Apr. 17, 2014.
Claims priority of provisional application 61/980,883, filed on Apr. 17, 2014.
Prior Publication US 2017/0333440 A1, Nov. 23, 2017
Int. Cl. C07D 487/14 (2006.01); C07D 487/20 (2006.01); C07D 471/20 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61K 31/527 (2006.01); A61K 31/519 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/519 (2013.01); A61K 31/527 (2013.01); A61K 45/06 (2013.01); C07D 487/14 (2013.01); C07D 487/20 (2013.01); C07D 471/20 (2013.01)] 10 Claims
 
1. A method for treating retinoblastoma (Rb)-positive breast cancer in a host comprising administering an effective amount to a host in need thereof, of a compound selected from:

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof.